Cardiological Findings in Children and Adolescents Before and After Guanfacine Treatment for Attention Deficit and Hyperactivity Disorder

被引:0
|
作者
Yukcu, Bekir [1 ]
Onal, Bedia Sultan [2 ]
Osmanli, Cansu Cobanoglu [2 ]
Tonkaz, Gulsum Yitik [2 ]
Sahin, Berkan [2 ]
机构
[1] Giresun Matern & Children Training & Res Hosp, Dept Pediat Cardiol, TR-28200 Giresun, Turkiye
[2] Giresun Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-28200 Giresun, Turkiye
来源
CHILDREN-BASEL | 2025年 / 12卷 / 03期
关键词
ADHD; guanfacine; cardiovascular safety; electrocardiography; EXTENDED-RELEASE GUANFACINE; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; ALPHA-2; AGONISTS; LONG-TERM; TP-E/QT; ADHD; STIMULANT; PSYCHOSTIMULANTS; METAANALYSIS;
D O I
10.3390/children12030302
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: This study evaluates the short-term cardiovascular effects of guanfacine treatment in children and adolescents with attention deficit/hyperactivity disorder (ADHD). The treatment's impact on novel electrocardiographic parameters was also investigated. Methods: In a retrospective study conducted between January 2023 and June 2024, 37 patients aged 6-18 years with ADHD underwent baseline and follow-up cardiac evaluations including electrocardiography (ECG) and blood pressure measurements. Novel ECG markers (QRS-T angle, QT dispersion, QTc dispersion, Tp-e interval, Tp-e dispersion, Tp-e/QT ratio, and Tp-e/QTc ratio) were analyzed alongside standard parameters such as heart rate, QT, and corrected QT (QTc) intervals. Guanfacine was initiated at 1 mg and titrated weekly until an optimal clinical response was achieved. Results: Guanfacine treatment led to a significant reduction in heart rate (-12.3 bpm; p < 0.001) and P wave axis (-12.3 degrees; p = 0.038) and an increase in QT interval (+16.8 ms; p = 0.014). However, no significant changes were observed in blood pressure, QTc duration, or the novel ECG parameters. Importantly, the absence of any changes in these advanced markers supports the cardiovascular safety of guanfacine. Two patients experienced side effects (bradycardia and hypotension), leading to treatment discontinuation. ANCOVA analysis indicated that the duration between ECG evaluations significantly influenced the QT interval changes, emphasizing the importance of timing when monitoring cardiovascular effects. Conclusions: Guanfacine demonstrated minor, statistically significant effects on the selected cardiac parameters without clinically meaningful changes to or adverse impacts on the novel ECG markers investigated. As extended-release guanfacine has only been available in T & uuml;rkiye for the management of ADHD for approximately two years, studies evaluating its clinical efficacy and side effects are critical for clinicians working in this field.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
    Newcorn, Jeffrey H.
    Huss, Michael
    Connor, Daniel F.
    Hervas, Amaia
    Werner-Kiechle, Tamara
    Robertson, Brigitte
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2020, 41 (07): : 565 - 570
  • [42] Amphetamines for attention deficit hyperactivity disorder in children and adolescents
    Feldman, Mark E.
    PAEDIATRICS & CHILD HEALTH, 2017, 22 (05) : 288 - +
  • [43] Attention-deficit/hyperactivity disorder in children and adolescents
    Dunn, DW
    Kronenberger, WG
    NEUROLOGIC CLINICS, 2003, 21 (04) : 933 - +
  • [44] Attention deficit hyperactivity disorder and enuresis in children and adolescents
    Zavadenko N.N.
    Kolobova N.M.
    Suvorinova N.Yu.
    Neuroscience and Behavioral Physiology, 2011, 41 (5) : 525 - 531
  • [45] Guanfacine Extended Release Adjunctive to a Psychostimulant in the Treatment of Comorbid Oppositional Symptoms in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
    Findling, Robert L.
    McBurnett, Keith
    White, Carla
    Youcha, Sharon
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2014, 24 (05) : 245 - 252
  • [46] Venlafaxine in children and adolescents with attention deficit hyperactivity disorder
    Mukaddes, NM
    Abali, O
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2004, 58 (01) : 92 - 95
  • [47] Treatment of attention deficit hyperactivity disorder in children
    Kehoe, WA
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) : 1130 - 1134
  • [48] Treatment of attention deficit hyperactivity disorder in children
    van der Oord, Saskia
    Prins, P. J. M.
    Oosterlaan, J.
    Emmelkamp, P. M. G.
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2008, 17 (02) : 73 - 81
  • [49] Methylphenidate in the treatment of children and adolescents with bipolar disorder and Attention-Deficit/Hyperactivity disorder
    Findling, Robert L.
    Short, Elizabeth J.
    McNamara, Nora K.
    Demeter, Christine A.
    Stansbrey, Robert J.
    Gracious, Barbara L.
    Whipkey, Resaca
    Manos, Michael J.
    Calabrese, Joseph R.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2007, 46 (11): : 1445 - 1453
  • [50] Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
    Spencer, Thomas J.
    Greenbaum, Michael
    Ginsberg, Lawrence D.
    Murphy, William Rory
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (05) : 501 - 510